Clinical trial
A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)
NCT00911807 is registered in ClinicalTrials.gov with Ever Neuro Pharma GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)
- Lead sponsor
- Ever Neuro Pharma GmbH
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2004
- Completion date
- April 30, 2008
- Enrollment
- 217 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.